Uncovering the Genetic Basis for Microbiome-Mediated Drug Metabolism
Principal Investigator: Andrew Goodman, Yale University
The overall goal of our research is to test the hypothesis that gut microbiome variation contributes to interpersonal differences in drug toxicity and efficacy. In this project, we are developing new approaches to identify and characterize microbiome-encoded drug metabolizing enzymes. If successful, results from this research could improve our understanding of drug responses across multiple disease indications.